PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

PCI Pharma Services, a Philadelphia-based biotherapy-focused contract development and manufacturing organization, has secured an investment co-led by Bain Capital and existing backer Kohlberg.

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

The company wrote, “An investment fund that receives investment advice from Bain Capital Private Equity (BCSF) and its corporate group has continuously made sincere proposals that it believe ...

However, KKR raised its offer price earlier this month to 9,850 yen ($65) per share from 9,451 yen, above Bain's most recent offer of 9,600 yen made in December.

Bain Capital Partners and Kohlberg Kravis Roberts & Co., two of the major investors of Nashville, Tenn.-based Hospital Corporation of America, said they will sell roughly 50 million shares of ...